These days the OXOLIFE team is in Milan (Italy) at European Society of Human Reproduction and Embryology (ESHRE) … [Read more...] about Oxolife attend to ESHRE Congress 2022
At @OXOLIFE we are celebrating!
After 9 months of recruiting women who are looking for pregnancy, we have finally passed our milestone with 403 patients … [Read more...] about At @OXOLIFE we are celebrating!
Oxolife in the News
Our CEO Agnes Arbat is interviewed at IB radio to talk about our OXOART2 Clinical trial. She explains the potential of … [Read more...] about Oxolife in the News
Oxolife initiates a collaboration with the University of Cordoba and Rutgers, The State University of New Jersey, to develop a treatment to improve women’s fertility
The biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of … [Read more...] about Oxolife initiates a collaboration with the University of Cordoba and Rutgers, The State University of New Jersey, to develop a treatment to improve women’s fertility
ANOTHER BIG MILESTONE FOR OXOLIFE
We are delighted to announce that OXOART2, the OXO-001 phase II clinical trial, has already started! As mentioned by … [Read more...] about ANOTHER BIG MILESTONE FOR OXOLIFE
Good feelings in the investigators meetings
On the 9th of September, we had the pleasure to meet the Czech and Polish investigators in the OXOART2 Investigators … [Read more...] about Good feelings in the investigators meetings